About Fabhalta® (iptacopan) Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway 6-7.

LOS ANGELES — When the U.S. Environmental Protection Agency began Phase 1 removal of household hazardous materials from ...

Amid fragile ceasefires in Gaza and Lebanon and shifting dynamics for Iran, Syria and others, the region is preparing for the ...

Compass Pathways has a financial cushion with cash reserves of $165.1 million, providing 4-6 quarters of runway before ...

Presale Phase 2 of Mutuum Finance (MUTM) is off to a flying start as investors rush to purchase tokens at $0.015 before the ...

MANDAN, ND ( KXNET) — The street improvement plan in Mandan set to upgrade the area around First Street is moving forward.

The USPS says 80% of services won’t be impacted by the move and all deliveries will still fall within the existing five-day service standard day range for First-Class Mail. Day ranges for end-to-end ...

The five-year survival rate of people diagnosed with pancreatic cancer is currently 13 percent. Two breakthroughs are ...

The Springfield Art Museum hosted a public “groundbreaking” event for Phase 1 of its transformative renovation and expansion ...

Several rare disease patient populations received their first-ever FDA-approved drug since Rare Disease Day last year, ...

Altimmune's pemvidutide shows promise in treating MASH and obesity, with upcoming Phase 2b results poised to shape its market ...

Steady growth at T Bar M Camps & Retreats—located at 2549 Hwy. 46—has inspired the Christian camp’s leadership team to expand ...